Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy

NCT07197112 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Acute Graft Versus Host Disease Grade II-IV
Acute Graft vs Host Disease

Interventions

DRUG: Gecacitinib

Sponsor

Ruijin Hospital